CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Dexmedetomidine 2 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01495481
NCT01495481N/ACompleted
CompareCT.gov

Dexmedetomidine Versus Adenosine: Electrophysiologic Effects and Therapeutic Use for Terminating Supraventricular Tachycardia

University of Pittsburgh·interventional·Posted Dec 20, 2011·Updated Mar 28, 2017

In Brief

A clinical study evaluating Dexmedetomidine and Adenosine for Supraventricular Tachycardia. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of dexmedetomidine in the acute termination of Supraventricular Tachycardia (SVT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSupraventricular Tachycardia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 20, 2011
Enrollment StartJan 1, 2012
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 14.5 years ago

Interventions

Dexmedetomidinedrug

Dexmedetomidine 2 mcg/kg, Intravenous push

Adenosinedrug

Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful